Public Health England

Systemic Anti Cancer Therapy (SACT)

Haematology SSCRG

Kellie Peters & Michael Wallington

National Disease Registration, CKO

Public Health England

What is Currently Available and How do I gain access?

Nationally →
- Coverage Map
- Numbers in Treatment
- Top Regimens

Area Team →
- Data Completeness
- Benchmarking

Hospital →
- Post Chemo Mortality
- Data Completeness
- Top Regimens



Public Health England

Coverage Map: A National Perspective

2nd September 2014



Key

Hospital trusts

- Submitting data

Total patients

- 1 to 5
- 5 to 25
- 25 to 40
- 40 to 150



London detail

Public Health England

So… what do the numbers tell us?

	July ‘13 to June’14	August ‘13 to July’14
Patients Receiving Drug Treatments	153,348	154,879
Regimens Commenced	250,131	254,162
Cycles Commenced	669,937	681,073

The figures listed above represent the number of patients reported to the CIU through SACT, for whom treatment activity has been submitted for the period covering August 2013 through July 2014 inclusive.

Public Health England

How good is the data nationally?

SACT data completeness, August 2013 to July 2014

England

Leukaemia

Key

- ↑ Increase in completeness since comparison period
- ↓ Decrease in completeness since comparison period
- → No change in completeness since comparison period
- ✓ 100% completion (for non-mandatory items)
- M Mandatory item (always 100%)

Number of patients	% NHS Number	% Date of Birth	% Current gender	% Ethnicity	% Patient postcode
6,447 ↑	100% M	100% M	98% →	92% →	100% M

Number of tumour records	% GP Practice Code	% GMC Code	% Consultant Specialty	% Primary diagnosis	% Morphology	% Stage of disease at start of programme
6,866 ↑	84% →	88% →	88% →	100% ✓	47% ↑	11% ↑

Number of regimens	% Programme number	% Regimen number	% Treatment intent	% Regimen name	% Height at start of regimen	% Weight at start of regimen	% Performance Status at start of regimen
11,429 ↑	66% ↑	57% →	71% ↑	100% M	44% →	51% ↑	28% ↑

% Comorbidity adjustment	% Date of decision to treat	% Start date of regimen	% Clinical trial	% Chemo radiation	% Number of cycles planned
36% ↑	77% →	100% M	72% →	59% ↑	55% ↑

Number of cycles	% Cycle number	% Start date of cycle	% Weight at start of cycle	% Performance Status at start of cycle	% OPCS procurement code	% of Cycles with Drug records
22,296 ↑	100% M	90% →	51% ↑	27% ↑	55% ↑	85% ↑

Number of drug records	% Drug name	% Actual dose per administration	% Administration route	% Administration date	% OPCS Delivery code	% Organisation code of drug provider
89,777 ↑	100% ✓	88% ↓	90% ↑	100% ✓	63% →	95% →

Number of outcome records	% Date of Final Treatment	% Regimen modification (dose reduction)	% Regimen modification (time delay)	% Regimen modification (stopped early)	% Regimen outcome summary	% Date of death
7,114 ↑	34% →	41% ↑	19% ↑	37% ↑	5% →	4% →

62% of regimens

Public Health England

How good is the data nationally?

SACT data completeness, August 2013 to July 2014

England

Lymphoma

Key

- ↑ Increase in completeness since comparison period
- ↓ Decrease in completeness since comparison period
- → No change in completeness since comparison period
- ✓ 100% completion (for non-mandatory items)
- M Mandatory item (always 100%)

Number of patients	% NHS Number	% Date of Birth	% Current gender	% Ethnicity	% Patient postcode
13,930 ↑	100% M	100% M	99% ↑	92% →	100% M

Number of tumour records	% GP Practice Code	% GMC Code	% Consultant Specialty	% Primary diagnosis	% Morphology	% Stage of disease at start of programme
15,705 ↑	84% →	87% →	87% ↑	100% ✓	46% ↑	16% ↑

Number of regimens	% Programme number	% Regimen number	% Treatment intent	% Regimen name	% Height at start of regimen	% Weight at start of regimen	% Performance Status at start of regimen
22,758 ↑	72% ↑	67% ↑	74% ↑	100% M	63% ↑	66% ↑	36% ↑

% Comorbidity adjustment	% Date of decision to treat	% Start date of regimen	% Clinical trial	% Chemo radiation	% Number of cycles planned
43% ↑	81% →	100% M	76% ↑	62% ↑	62% ↑

Number of cycles	% Cycle number	% Start date of cycle	% Weight at start of cycle	% Performance Status at start of cycle	% OPCS procurement code	% of Cycles with Drug records
54,495 ↑	100% M	94% ↑	66% ↑	37% ↑	57% ↑	83% ↑

Number of drug records	% Drug name	% Actual dose per administration	% Administration route	% Administration date	% OPCS Delivery code	% Organisation code of drug provider
213,975 ↑	100% ✓	94% ↓	94% ↑	100% ✓	62% ↑	96% →

Number of outcome records	% Date of Final Treatment	% Regimen modification (dose reduction)	% Regimen modification (time delay)	% Regimen modification (stopped early)	% Regimen outcome summary	% Date of death
15,328 ↑	34% ↑	48% ↑	20% ↑	42% ↑	5% →	3% →

67% of regimens

Public Health England

How good is the data nationally?

SACT data completeness, August 2013 to July 2014

England

Myeloma

Key

- ↑ Increase in completeness since comparison period
- ↓ Decrease in completeness since comparison period
- → No change in completeness since comparison period
- ✓ 100% completion (for non-mandatory items)
- M Mandatory item (always 100%)

Number of patients	% NHS Number	% Date of Birth	% Current gender	% Ethnicity	% Patient postcode
7,170 ↑	100% M	100% M	99% ↑	94% ↑	100% M

Number of tumour records	% GP Practice Code	% GMC Code	% Consultant Specialty	% Primary diagnosis	% Morphology	% Stage of disease at start of programme
7,707 ↑	85% →	89% ↑	89% ↑	100% ✓	47% ↑	15% ↑

Number of regimens	% Programme number	% Regimen number	% Treatment intent	% Regimen name	% Height at start of regimen	% Weight at start of regimen	% Performance Status at start of regimen
12,977 ↑	73% ↑	65% →	74% ↑	100% M	49% →	52% →	35% →

% Comorbidity adjustment	% Date of decision to treat	% Start date of regimen	% Clinical trial	% Chemo radiation	% Number of cycles planned
45% ↑	85% ↑	100% M	77% →	61% ↑	58% →

Number of cycles	% Cycle number	% Start date of cycle	% Weight at start of cycle	% Performance Status at start of cycle	% OPCS procurement code	% of Cycles with Drug records
33,058 ↑	100% M	93% ↑	51% ↑	35% ↑	42% ↑	87% ↑

Number of drug records	% Drug name	% Actual dose per administration	% Administration route	% Administration date	% OPCS Delivery code	% Organisation code of drug provider
88,840 ↑	100% ✓	91% ↓	91% ↑	100% ✓	54% ↑	96% →

Number of outcome records	% Date of Final Treatment	% Regimen modification (dose reduction)	% Regimen modification (time delay)	% Regimen modification (stopped early)	% Regimen outcome summary	% Date of death
8,770 ↑	32% →	48% ↑	22% ↑	42% →	5% →	4% →

68% of regimens

Public Health England

How good is my data, compared to hospitals in my area team?

Diagnostic Group > NHS England Area Team > Hospital Trust	Number of patients	Number of tumour records	Number of regimens	Number of cycles	Number of drug records	Number of outcome records	% Primary diagnosis	% Morphology	% Programme number	% Treatment intent	% Regimen name	% Start date of cycle	% Drug name	% Actual dose per administration	% Date of Final Treatment	% Regimen outcome summary
Leukaemia	**6,447**	**6,866**	**11,429**	**22,296**	**89,777**	**7,114**	**100%**	**47%**	**66%**	**71%**	**100%**	**90%**	**100%**	**88%**	**34%**	**5%**
London Commissioning Region	**1,264**	**1,276**	**2,964**	**6,165**	**20,015**	**1,341**	**100%**	**46%**	**44%**	**49%**	**100%**	**73%**	**100%**	**86%**	**26%**	**2%**
Barking, Havering and Redbridge University Hospitals NHS Trust	13	13	14	56	279	14	100%	0%	57%	100%	100%	100%	100%	100%	0%	0%
Barts Health NHS Trust	238	238	435	612	3,481	434	100%	36%	68%	99%	100%	96%	100%	100%	17%	13%
Chelsea and Westminster Hospital NHS Foundation Trust	12	12	12	18	35	12	100%	17%	92%	100%	100%	100%	100%	100%	0%	0%
Croydon Health Services NHS Trust	6	6	6	15	29		100%	100%	100%	100%	100%	100%	100%	100%		
Ealing Hospital NHS Trust	11	11	11	60	125	11	100%	0%	100%	100%	100%	100%	100%	99%	18%	27%
Epsom and St Helier University Hospitals NHS Trust	45	45	57	85			100%	0%	0%	0%	100%	0%				
Great Ormond Street Hospital For Children NHS Foundation Trust	71	71	129	149	779	129	100%	94%	100%	100%	100%	100%	100%	100%	71%	1%
Guy's and St Thomas' NHS Foundation Trust	52	53	75	396	659	75	100%	4%	44%	99%	100%	100%	100%	100%	100%	1%
Homerton University Hospital NHS Foundation Trust																
Imperial College Healthcare NHS Trust																
King's College Hospital NHS Foundation Trust	50	50	73	132			100%	0%	15%	12%	100%	8%				
Kingston Hospital NHS Trust	17	17	17	50	172	12	100%	71%	100%	100%	100%	100%	100%	99%	24%	24%
Lewisham Healthcare NHS Trust	24	25	36	65	46	12	100%	12%	0%	33%	100%	100%	100%	100%	0%	0%
North Middlesex University Hospital NHS Trust	9	9	9	34	73	6	100%	67%	67%	67%	100%	82%	100%	99%	22%	0%
North West London Hospitals NHS Trust	22	25	29	30	103	21	100%	0%	72%	17%	100%	73%	100%	0%	0%	0%
Royal Free London NHS Foundation Trust	42	44	91	145	1,224	40	100%	100%	99%	89%	100%	42%	100%	100%	37%	1%
St George's Healthcare NHS Trust	48	48	100	222	844	89	100%	0%	100%	100%	100%	100%	100%	100%	80%	1%
The Hillingdon Hospitals NHS Foundation Trust	24	24	24	24			100%	4%	4%	0%	100%	0%				
The Royal Marsden NHS Foundation Trust	358	359	1,352	3,203	6,373	9	100%	100%	7%	7%	100%	60%	100%	68%	0%	0%
The Whittington Hospital NHS Trust	2	2	3	6			100%	0%	0%	100%	100%	0%				
University College London Hospitals NHS Foundation Trust	211	215	478	832	5,678	464	100%	0%	97%	92%	100%	99%	100%	87%	85%	0%
West Middlesex University Hospital NHS Trust	9	9	13	31	115	13	100%	33%	62%	100%	100%	87%	100%	100%	23%	8%

Public Health England

Can I find out how complete my hospital's Brain/CNS data is?

SACT Data Completeness Profile

Trust
All diagnostic groups, activity between 01/09/2013 and 30/09/2013

Key: • = 100% complete
• = Better than England average
• = Worse than England average

Trust Name	Total Patients	Total Tumours	Total Regimens	Total Cycles	Total Drugs	Total Outcomes
NHS Foundation Trust	781	788	805	1,149	8,576	805

	% NHS Number*	% Date of Birth*	% Gender	% Ethnicity	% Post Code*
Total Patients: 781	• 100.0%	• 100.0%	• 100.0%	• 89.0%	• 100.0%
England average:	100.0%	100.0%	98.2%	92.5%	100.0%

	% GP Practice Code	% Consultant GMC code	% Consultant Speciality	% Primary Diagnosis*	% Morphology*	% Stage
Total Tumours: 788	• 100.0%	• 72.0%	• 70.9%	• 100.0%	• 64.5%	• 24.2%
England average:	76.6%	87.5%	90.1%	100.0%	46.3%	28.1%

	% Programme Number	% Regimen Number	% Treatment Intent	% Height at Regimen Start	% Weight at Regimen Start	% Performance Status at Regimen Start
Total Regimens: 805	• 100.0%	• 100.0%	• 96.0%	• 82.2%	• 82.2%	• 99.8%
England average:	54.0%	67.2%	79.9%	55.7%	55.7%	38.5%

	% Co-Morbitiy Adjustment	% Decision To Treat Date	% Regimen Start Date*	% Clinical Trial	% Chemo Radiation	% Cycles Planned
	• 0.0%	• 66.8%	• 100.0%	• 100.0%	• 100.0%	• 100.0%
England average:	38.4%	84.9%	100.0%	76.6%	55.8%	58.7%

	% Regimen Name*	% Regimen matching OPCS 4.6	% Regimen mapped by CIU	% Regimen mapped to TRIAL	% Regimen mapped to NOT CHEMO
	• 100.0%	42.6%	50.0%	7.4%	0.0%
England average:	100.0%				

	% Cycle Number*	% Cycle Start Date	% Weight at Cycle Start	% Performance Status at Cycle Start	% OPCS Procurement Code
Total Cycles: 1,149	• 100.0%	• 99.0%	• 13.8%	• 99.7%	• 69.4%
England average:	100.0%	95.9%	48.8%	31.5%	48.9%

	% Drug Name	% Dose	% Route of Administration	% Date of Administration	% Organisation Code of Drug Provider	% OPCS Delivery Code
Total Drugs: 8,576	• 100.0%	• 98.0%	• 100.0%	• 100.0%	• 100.0%	• 70.9%
England average:	100.0%	94.5%	91.3%	100.0%	94.6%	58.0%

	% Final Treatment Date	% Regimen Modificaiton Dose Reduction	% Regimen Modification Time Delay	% Regimen Modification Stopped Early	% Regimen Outcome Summary	% Date of Death
Total Outcomes: 805	3.5%	100.0%	100.0%	100.0%	100.0%	0.5%

* Mandatory fields are denoted with an asterisk

Report executed on 12 November 2013; Source: SACT.

SACT Data Quality Profile

Trust
Reported activity taking place between 01/09/2013 and 30/09/2013

ciu NCIN

1. Morphology completion for critical diagnostic groups
Proportion of patients in each diagnostic group with morphology recorded

Gynae (Ovarian)	Lung	Urology (Testis)
98% 53 out of 54 patients	80% 35 out of 44 patients	80% 4 out of 5 patients

2. Intent of Treatment by diagnostic group
Total number of patients treated between 01/09/2013 and 30/09/2013 with treatment intent recorded.
Percentages are aggregated by diagnostic group. Patients with multiple treatment intent recorded will be double-counted.

	Adjuvant	Curative	Disease Modification	Neo-adjuvant	Palliative	Not recorded
Brain/CNS	9 (24%)	15 (39%)	0 (0%)	0 (0%)	14 (37%)	0 (0%)
Breast	63 (47%)	7 (5%)	0 (0%)	19 (14%)	39 (29%)	5 (4%)
Gynae	20 (24%)	7 (8%)	0 (0%)	9 (11%)	48 (58%)	1 (1%)
Head and Neck	0 (0%)	8 (80%)	0 (0%)	0 (0%)	2 (20%)	0 (0%)
Leukaemia	2 (4%)	13 (27%)	0 (0%)	0 (0%)	34 (69%)	0 (0%)
Lower GI	24 (35%)	6 (9%)	0 (0%)	2 (3%)	36 (52%)	1 (1%)
Lung	2 (4%)	4 (9%)	0 (0%)	0 (0%)	39 (87%)	0 (0%)
Lymphoma	0 (0%)	36 (55%)	0 (0%)	0 (0%)	29 (45%)	0 (0%)
Miscellaneous	2 (5%)	4 (9%)	0 (0%)	0 (0%)	36 (82%)	2 (5%)
Myeloma	2 (4%)	2 (4%)	0 (0%)	0 (0%)	42 (91%)	0 (0%)
Sarcoma	1 (17%)	0 (0%)	0 (0%)	0 (0%)	5 (83%)	0 (0%)
Skin	0 (0%)	2 (8%)	0 (0%)	0 (0%)	23 (92%)	0 (0%)
Upper GI	2 (5%)	5 (12%)	0 (0%)	1 (2%)	32 (76%)	2 (5%)
Urology	11 (16%)	3 (4%)	0 (0%)	0 (0%)	43 (64%)	10 (15%)

3. Number of cycles reported
Number of cycles reported by cycle start date and corresponding regimen start category (*'In month' or 'Prior'*).
Percentages are aggregated by month of cycle start.

	Regimen Start Date		
Month of cycle start	In month	Missing Cycle Start Date	Prior
April 2013	183 (20%)	10 (1%)	726 (79%)
May 2013	214 (23%)	25 (3%)	679 (74%)
June 2013	206 (24%)	17 (2%)	629 (74%)
July 2013	181 (19%)	15 (2%)	756 (79%)
August 2013	213 (23%)	10 (1%)	714 (76%)
September 2013	195 (22%)	10 (1%)	680 (77%)



Source: SACT dataset, accessed 12/11/2013

Page 1 of 1

Number of Patients by Diagnostic Group

All submitting trusts aggregated

Data received for July 2013 - June 2014. Patients aged 16 and over



Top Regimens by Diagnostic Group

Leukaemia (ALL)

ICD10: C910, C915, C918

These reports are available at a provider level

There are in excess of 90 regimens for this disease group

All submitting trusts aggregated

Data received for July 2013 – June 2014.

Patients aged 16 and over



Top Regimens by Diagnostic Group

Leukaemia (AML)

ICD10: C920, C923-C926, C928, C93, C942-C944, C962, C964, C968

These reports are available at a provider level

There are in excess of 140 regimens for this disease group

All submitting trusts aggregated

Data received for July 2013 – June 2014.

Patients aged 16 and over



Top Regimens by Diagnostic Group

Leukaemia (CLL)

ICD10: C911

These reports are available at a provider level

There are in excess of 100 regimens for this disease group

All submitting trusts aggregated

Data received for July 2013 – June 2014.

Patients aged 16 and over



Top Regimens by Diagnostic Group

Leukaemia (CML)

ICD10: C921

These reports are available at a provider level

There are in excess of 30 regimens for this disease group

All submitting trusts aggregated

Data received for July 2013 – June 2014.

Patients aged 16 and over



Top Regimens by Diagnostic Group

Lymphoma (Hodgkin lymphoma)

ICD10: C81

These reports are available at a provider level

There are in excess of 120 regimens for this disease group

All submitting trusts aggregated

Data received for July 2013 – June 2014.

Patients aged 16 and over



Top Regimens by Diagnostic Group

Lymphoma (NHL aggressive)

ICD10: C824, C831, C835, C837, C846-C847, C852

These reports are available at a provider level

There are in excess of 230 regimens for this disease group

All submitting trusts aggregated

Data received for July 2013 – June 2014.
Patients aged 16 and over



Top Regimens by Diagnostic Group

Lymphoma (NHL indolent)

ICD10: C82, C830, C884, C913-C914, C916-C917, C919

These reports are available at a provider level

There are in excess of 160 regimens for this disease group

All submitting trusts aggregated

Data received for July 2013 – June 2014.

Patients aged 16 and over



Regimen benchmarking

Lymphoma (NHL) ICD10: C82-C86, C88, C913-C914, C916-C917, C919

Data received for April 2013 - March 2014.

NHS England Area Team comparison; Includes activity from trusts where more than 50 patients aged 16 and over received treatment



Regimen benchmarking

Lymphoma (NHL) ICD10: C82-C86, C88, C913-C914, C916-C917, C919

Data received for April 2013 - March 2014.
London Commissioning Region; Trusts included where more than 50 patients aged 16 and over received treatment



Regimen benchmarking

Myeloma (All) ICD10: C90, D472, E85

Data received for April 2013 - March 2014.

NHS England Area Team comparison; Includes activity from trusts where more than 50 patients aged 16 and over received treatment



Regimen benchmarking

Myeloma (All) ICD10: C90, D472, E85

Data received for April 2013 - March 2014.

Bristol, North Somerset, Somerset and South Gloucestershire; Trusts included where more than 50 patients aged 16 and over received treatment



Public Health England

Post Chemotherapy Mortality Analysis

✓ From **25th July 2014** all NHS providers of chemotherapy in England will be able to access their 30/60/90-day post chemotherapy mortality analysis through the **secure online portal**.

✓ This analysis is available by tumour group and will provide a national comparison.

✓ **It is essential that clinical teams** within provider organisations check the accuracy of their data and contact the team in Oxford where there are **any possible discrepancies**.

✓ A letter to Medical Directors and Lead Chemotherapy Consultants has been sent out raising awareness of these reports.

Public Health England

Post Chemotherapy Mortality Analysis (2)

Trust	NHS Foundation Trust	Diagnostic Group	Leukaemia, Lymphoma, Myelom
Intent of treatment	All treatment intents	Show regimens with no deaths?	No, only show regimens with recorded death
Sort by	Total deaths within 30 days (highest to lowest)	Start Date	January 2013
End Date	December 2013		

View Report

3 of 4 Find | Next

Post-chemotherapy mortality analysis (January 2013 - December 2013)

Source: SACT, ENCORE (CAS) and Personal Demographics Service (PDS), accessed 15th May 2014

For demonstration purposes only

	Total patients	Deaths 0-30 days	Death 0-60 days	Deaths 0-90 day	Total deaths
NHS Foundation Trust	**1,502**	**121**	**224**	**312**	**532**

	Total patients	Deaths 0-30 days	Death 0-60 days	Deaths 0-90 day	Total deaths
Lymphoma	**239**	**15**	**26**	**32**	**39**
Curative	**193**	**11**	**20**	**24**	**28**
BORTEZOMIB	2	2	2	2	2
RITUXIMAB	55	2	3	4	5
LEAM	26	1	3	4	4
CYTARABINE + METHOTREXATE HD	4	1	1	1	2
METHOTREXATE INTRATHECAL	7	1	1	1	1
CVP R	4	1	1	1	1
ETOPOSIDE	1	1	1	1	1
VINCRISTINE	1	1	1	1	1
GEMCITA[illegible]CLITAXEL	3	1			3

Public Health England

Post Chemotherapy Survival Analysis Hodgkin's Lymphoma

For demonstration purposes only



Public Health England

Post Chemotherapy Survival Analysis
Chronic Lymphocytic Leukaemia

For demonstration purposes only



Public Health England

Online Regimen Mapping Tool Launched

- ✓ Providers now have the responsibility to map their local regimen names to nationally recognised regimen nomenclature using the new mapping tool.
- ✓ The tool was tested by members of the SACT User Group, before being launched on the upload portal.
- ✓ Using feedback, the written guidelines and step by step guide have been produced in conjunction with senior pharmacists who are supporting the team.
- ✓ We currently have over 50 registered users with the new role of “Regimen mapping”

Public Health England

We want to identify best practice across England and share it!

- **Have You**:
  - Improved SACT data quality by introducing new processes?
  - Used your local SACT data to improve services, or your understanding of chemotherapy?
  - Shared all SACT reports (Data Quality, Top Regimen, Benchmarking and the mortality reports) with your pharmacy and oncology teams members in order to improve understanding SACT and its purpose?

If yes, please contact us at CIU@phe.gov.uk!

Public Health England

Improving Stakeholder Engagement

Members of the CIU team will be attending the following meetings in August / September:

- NHS England Area Team Pharmacist Meeting
- NCIN Breast Site Specific Clinical Reference Group (SSCRG)
- NCIN Lung SSCRG
- NHS England Chemotherapy Clinical Reference Group
- NCIN Central Nervous System SSCRG
- NCIN Haematology SSCRG

Would you like to know more about SACT? Please contact the team, we are always happy to discuss the project or meet with you.

E-mail: CIU@phe.gov.uk